MRI-guided Radiation Therapy Systems - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The MRI-guided radiation therapy systems market size was valued at USD 0.85 billion in 2025 and is estimated to grow from USD 0.95 billion in 2026 to reach USD 1.72 billion by 2031, at a CAGR of 12.52% during the forecast period (2026-2031). This report is segmented by Product Type (Integrated MR-Linac Systems, and More), MRI Field Strength (0. 3 Tesla To 0. 5 Tesla Systems and More), Clinical Application (Prostate, Pancreatic, Liver, and More), End User (Hospitals, Academic Medical Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global MRI-guided Radiation Therapy Systems Market Trends and Insights

Rising Cancer Incidence and Radiotherapy Treatment Demand

Rising cancer incidence is expanding the patient population requiring radiotherapy across established and developing healthcare systems. The World Health Organization reported 20.6 million new cancer cases in 2024 and projects 35 million cases annually by 2050. This trend supports demand in the MRI-guided radiation therapy systems market, particularly for prostate, pancreatic, liver, and thoracic tumors that require precise soft-tissue and adjacent-organ visualization. MRI-guided treatment supports smaller margins and adaptive radiotherapy workflows by addressing organ-motion uncertainty in conventional CT-guided planning; a 2026 review reported advantages in target localization, organ-motion management, and dosimetric control.

Adoption of Online Adaptive and Motion-Gated Radiotherapy

Online adaptive treatment is gaining traction as it enables treatment plans to respond to anatomical changes on the day of care. The MOMENTUM registry enrolled 630 patients across 12 centers in North America and Europe under NCT04075305. At the 2025 ASTRO Annual Meeting, patients receiving daily adaptive recontouring reported lower urinary symptom scores than those receiving non-adaptive MR-guided treatment: 2.2 versus 7.7 at 3 months, 3.0 versus 6.6 at 6 months, and 2.8 versus 8.8 at 12 months. A 2026 prospective phase II study reported 87.4% 2-year biochemical and clinical progression-free survival, zero late grade ≥2 toxicities, and 100% in-field control across prostate, pelvic nodal, and oligometastatic lesions, supporting procurement decisions beyond research-focused use.

High Capital, Installation and Maintenance Costs

MR-Linac deployment requires significant capital investment in shielding, specialized infrastructure, commissioning, and ongoing service support. These requirements create challenges for smaller hospitals and health systems with limited medical physics resources. MagnetTx designed Aurora-RT with a cryogen-free 0.5 Tesla superconducting magnet and rotating gantry, eliminating liquid-helium refill requirements. Siemens Healthineers offers the 0.55 Tesla MAGNETOM Free.Max RT Pro Edition, featuring a 165 cm system length and a quench-pipe-free design for facilities with infrastructure constraints. However, equipment selection, regulatory compliance, quality assurance, and workforce capacity continue to complicate procurement.

Other drivers and restraints analyzed in the detailed report include:

• AI-Assisted Contouring and Synthetic CT Workflows
• Expansion of High-Value Applications in Pancreatic, Liver, and Lung Cancers
• Limited Reimbursement and Incomplete Comparative Clinical Evidence

Segment Analysis

Integrated MR-Linac systems accounted for 67.88% of the MRI-guided radiation therapy systems market share in 2025 and are projected to grow at a 16.39% CAGR through 2031. These systems combine MRI and a linear accelerator within a single treatment platform, supporting real-time visualization during beam delivery for targets affected by anatomical changes or motion. Full integration provides greater clinical control than workflows using separately located imaging and treatment systems. Elekta Unity remains the commercially established 1.5 Tesla integrated platform with the broadest cited multicenter clinical evidence base.

A 2025 dosimetric comparison of 20 MRIdian clinical cases recreated on Unity found comparable plan quality across the platforms. Unity showed modest reductions in rectal V36-40Gy for prostate cases and mean liver dose for pancreatic cases. These results support the continued use of integrated systems for complex disease sites.

The 1.5 Tesla segment held 55.45% of the MRI-guided radiation therapy systems market share in 2025. Its leadership reflects the superior soft-tissue imaging quality available at higher magnetic field strengths. High-field systems have developed a substantial clinical evidence base through prostate registries, glioma research, and emerging lung-treatment studies. The UNITED glioma trial was published in The Lancet Oncology in 2026.

Systems in the 0.3 Tesla to 0.5 Tesla range are forecast to grow at a 15.34% CAGR through 2031. Their growth reflects lower infrastructure requirements, simpler siting, and designs that manage the electron return effect. ViewRay MRIdian uses a 0.35 Tesla split MRI configuration with the beam perpendicular to the magnetic field. MagnetTx Aurora-RT uses a 0.5 Tesla rotating biplanar magnet with the beam parallel to the field, avoiding the electron return effect without beam-modeling corrections. Siemens Healthineers offers the 0.55 Tesla MAGNETOM Free. Max RT Pro Edition is an MR-simulation system that can be installed near existing treatment rooms. These architectures provide oncology providers with multiple pathways to MRI-enabled radiotherapy. Lower-field systems can be relevant in India, China, and other Asia-Pacific markets where a 1.5 Tesla installation may be difficult to support.

Complete Report Scope:

• By Product Type
  • Integrated MR-Linac Systems
  • MRI-Guided Cobalt-60 Systems
  • MRI-Guided Linear Accelerator Systems
• By MRI Field Strength
  • 0.3 Tesla to 0.5 Tesla Systems
  • 1.5 Tesla Systems
• By Clinical Application
  • Prostate Cancer
  • Pancreatic Cancer
  • Liver Cancer and Liver Metastases
  • Lung Cancer
  • Breast Cancer
  • Others
• By End User
  • Hospitals
  • Academic Medical Centers
  • Dedicated Cancer Centers
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.80% of the MRI-guided radiation therapy systems market share in 2025. The region benefits from National Cancer Institute-designated cancer centers, established radiation physics training programs, and reimbursement advocacy for adaptive radiotherapy. The United States accounts for a significant installed base, with clinical programs at Moffitt Cancer Center, Washington University, and UCLA, while Elekta signed a collaboration agreement with Moffitt Cancer Center in February 2025. Canada contributes through MagnetTx Oncology Solutions and the Northern Lights Clinical Consortium; however, reimbursement and treatment throughput remain key barriers to broader deployment.

Europe is the second-largest region in the MRI-guided radiation therapy systems market. Medical centers across Germany, the Netherlands, the United Kingdom, France, and Spain support multicenter registries and clinical validation. Institut Curie activated an Elekta Unity MR-Linac at its Saint-Cloud site in March 2025, supported by EUR 10 million (USD 11.61 million) in institutional and government funding. Siemens Healthineers received CE marking for Eclipse AI contouring integration at ESTRO 2026, while health technology assessment and tariff decisions in Germany and the United Kingdom will influence broader adoption.

Asia-Pacific is projected to grow at a CAGR of 14.56% through 2031, driven by rising cancer burden, public oncology infrastructure investment, and expanding cancer-center networks. India introduced its first Elekta Unity MR-Linac with Comprehensive Motion Management at Yashoda Medicity in Hyderabad in 2025, while China initiated institutional procurement, including a single-source tender by Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine. Japan began clinical treatment with a 1.5 Tesla MR-Linac in December 2021, although adoption remains concentrated around Kanto cancer centers. South Korea, Australia, the Middle East and Africa, and South America represent additional demand areas, with Brazil leading oncology-capacity investment in South America; infrastructure and workforce limitations will influence adoption.

List of Companies Covered in this Report:

• Elekta
• Koninklijke Philips
• MagnetTx Oncology Solutions
• Siemens Healthineers AG (Varian Medical Systems, Inc.)
• ViewRay Technologies

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support